78 studies found for:    INCB018424 | Exclude Unknown
Show Display Options
Rank Status Study
1 Recruiting Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)
Condition: Leukemia
Interventions: Drug: Ruxolitinib;   Drug: TKI
2 Not yet recruiting Study of Ruxolitinib Plus Decitabine in Patients With Acute Myeloid Leukemia (AML)
Conditions: Leukemia;   Myeloproliferative Diseases
Interventions: Drug: Ruxolitinib;   Drug: Decitabine
3 Not yet recruiting Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)
Condition: Myeloproliferative Diseases
Interventions: Drug: Ruxolitinib;   Drug: Pracinostat;   Behavioral: Questionnaire
4 Completed
Has Results
Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients
Condition: Myelofibrosis
Intervention: Drug: Ruxolitinib
5 Recruiting Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Condition: Leukemia
Intervention: Drug: Ruxolitinib
6 Completed A Study of INCB018424 Phosphate Cream When Applied to Patients With Plaque Psoriasis
Condition: Plaque Psoriasis
Interventions: Drug: INCB018424 phosphate cream;   Drug: Dovonex® calcipotriene 0.005%;   Drug: Diprolene® AF betamethasone dipropionate 0.05% cream.;   Drug: Placebo cream
7 Recruiting Ruxolitinib Prior to Transplant in Patients With Myelofibrosis
Conditions: Primary Myelofibrosis;   Post Polycythemia Vera Myelofibrosis;   Post Essential Thrombocythemia Myelofibrosis
Intervention: Drug: Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)
8 Active, not recruiting Phase l/II Study of Ruxolitinib for Acute Leukemia
Condition: Leukemia
Intervention: Drug: Ruxolitinib
9 Recruiting A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)
Condition: Primary Myelofibrosis
Intervention: Drug: Ruxolitinib
10 Recruiting Study of Ruxolitinib in Colorectal Cancer Patients
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Ruxolitinib;   Drug: Regorafenib;   Drug: Placebo
11 Recruiting Administration of Jakafi (Ruxolitinib) for Symptom Control of Patients With Chronic Lymphocytic Leukemia (CLL): Phase II
Condition: Leukemia
Interventions: Drug: Ruxolitinib;   Behavioral: Questionnaire
12 Active, not recruiting Ruxolitinib and Lenalidomide for Patients With Myelofibrosis
Condition: Myeloproliferative Diseases
Interventions: Drug: Ruxolitinib;   Drug: Lenalidomide;   Drug: Prednisone
13 Active, not recruiting
Has Results
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
Condition: Myelofibrosis
Interventions: Drug: Ruxolitinib;   Drug: Placebo
14 Active, not recruiting
Has Results
Study to Determine the Safety and Efficacy of Ruxolitinib (INCB018424) in Patients With Polycythemia Vera or Essential Thrombocythemia
Conditions: Polycythemia Vera;   Essential Thrombocythemia
Intervention: Drug: Ruxolitinib
15 Completed
Has Results
Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis
Intervention: Drug: Ruxolitinib
16 Terminated
Has Results
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
Condition: Metastatic Prostate Cancer
Intervention: Drug: Ruxolitinib
17 Active, not recruiting INCB018424 in Patients With Advanced Hematologic Malignancies
Conditions: Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Myelodysplastic Syndrome;   Chronic Myelogenous Leukemia
Intervention: Drug: INCB018424
18 Recruiting Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.
Condition: Polycythemia Vera
Interventions: Drug: Best Available Therapy;   Drug: ruxolitinib
19 Completed
Has Results
A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma
Conditions: Relapsed Multiple Myeloma;   Refractory Multiple Myeloma;   Multiple Myeloma
Interventions: Drug: Ruxolitinib 25 mg;   Drug: Dexamethasone 40 mg
20 Active, not recruiting
Has Results
Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
Conditions: Myelofibrosis;   Polycythemia Vera;   Thrombocytosis
Intervention: Drug: Ruxolitinib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years